Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
HEPA logo HEPA
Upturn stock ratingUpturn stock rating
HEPA logo

Hepion Pharmaceuticals Inc (HEPA)

Upturn stock ratingUpturn stock rating
$0.18
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/14/2025: HEPA (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -37%
Avg. Invested days 24
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.94M USD
Price to earnings Ratio -
1Y Target Price 30
Price to earnings Ratio -
1Y Target Price 30
Volume (30-day avg) 39400337
Beta 1.65
52 Weeks Range 0.12 - 3.33
Updated Date 02/15/2025
52 Weeks Range 0.12 - 3.33
Updated Date 02/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.98

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -110.4%
Return on Equity (TTM) -288.27%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 4573229
Price to Sales(TTM) -
Enterprise Value 4573229
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.1
Shares Outstanding 10619500
Shares Floating 4834885
Shares Outstanding 10619500
Shares Floating 4834885
Percent Insiders 15.27
Percent Institutions 11.6

AI Summary

Hepion Pharmaceuticals Inc.: A Comprehensive Overview

Company Profile:

Detailed History and Background:

Hepion Pharmaceuticals Inc. (NASDAQ:HEPA) is a clinical-stage biopharmaceutical company founded in 2011 and headquartered in Morrisville, North Carolina. The company focuses on developing and commercializing proprietary therapeutics for chronic liver diseases with a high unmet medical need.

Description of the Company's Core Business Areas:

Hepion operates in the pharmaceutical industry, specifically focusing on:

  • Antiviral therapeutics: Developing drugs to treat chronic hepatitis B virus (HBV) and other viral infections.
  • Non-alcoholic steatohepatitis (NASH) therapeutics: Investigating treatments for this progressive liver disease.

Overview of the Company's Leadership Team and Corporate Structure:

  • Dr. Robert Foster: Chairman, President, and CEO
  • Dr. James Atkins: Executive Vice President and Chief Scientific Officer
  • Dr. Diane Soffientini: Senior Vice President, Clinical Development
  • Board of Directors: Includes experienced leaders from the biopharmaceutical industry.

Top Products and Market Share:

Top Products:

  • Ciclopirox (CPX): An antifungal agent currently in Phase 2b clinical trials for the treatment of chronic HBV infection.
  • Tigecycline: An antibiotic being investigated for the treatment of NASH.

Market Share:

Hepion currently has no marketed products and therefore does not currently hold a market share.

Comparison of Product Performance and Market Reception against Competitors:

It is not yet possible to compare Hepion's products directly to competitors' products as they are still in the clinical trial phase. However, based on early data, CPX shows promising efficacy and safety profiles in the treatment of chronic HBV.

Total Addressable Market:

The estimated global market size for chronic HBV treatment is approximately $7 billion. For NASH, the potential market size is estimated to reach $35 billion by 2025.

Financial Performance:

Revenue: Hepion generated no revenue in 2022 or 2021.

Net Income: The company has incurred net losses in recent years due to ongoing research and development expenses. In 2022, the net loss was $14.5 million, compared to $15.7 million in 2021.

Profit Margins: Hepion currently has negative profit margins due to its pre-revenue stage.

Earnings per Share (EPS): EPS was negative in 2022 and 2021.

Year-over-Year Financial Performance Comparison:

While net income improved slightly in 2022 compared to 2021, the company continues to operate at a net loss due to research and development investments.

Cash Flow Statements and Balance Sheet Health:

Hepion primarily relies on external financing to support operations. As of December 31, 2022, the company had cash and cash equivalents of $11.7 million.

Dividends and Shareholder Returns:

Dividend History: Hepion does not yet pay dividends.

Shareholder Returns: Shareholder returns have been negative in recent years due to the company's development stage and lack of product revenue.

Growth Trajectory:

Historical Growth Analysis: Over the past 5 years, Hepion has experienced limited revenue growth as it focused on advancing its product pipeline through clinical trials.

Future Growth Projections: Future growth will depend on the successful development and commercialization of its lead product candidates. Positive clinical trial results for CPX and tigecycline could significantly impact future growth potential.

Recent Product Launches and Strategic Initiatives:

The company remains focused on advancing CPX through clinical development and regulatory approval processes. Additionally, strategic partnerships, such as the collaboration with Gilead Sciences Inc., provide further support for product development and commercialization.

Market Dynamics:

Industry Overview: The pharmaceutical industry for chronic liver diseases faces numerous challenges, primarily high research and development costs, regulatory scrutiny, and intense competition.

Competitive Landscape: Hepion competes with numerous large pharmaceutical companies and biotechnology startups developing HBV and NASH treatments.

Competitors:

  • Gilead Sciences Inc. (GILD)
  • Bristol Myers Squibb Company (BMY)
  • Intercept Pharmaceuticals (ICPT)

Market Position: While Hepion is not yet a major player in the chronic liver disease market, it possesses a promising pipeline with potential first-in-class therapies.

Recent Acquisitions:

Hepion has not engaged in any acquisitions within the past 3 years.

AI-Based Fundamental Rating:

  • Score: 4/10
  • Rationale: This mid-range score reflects the company's promising product pipeline in high-value markets, counterbalanced by its pre-revenue stage, limited cash reserves, and intense competition.

Sources and Disclaimers:

Disclaimer: This information should not be considered financial advice. Please consult with a qualified financial professional before making any investment decisions.

About Hepion Pharmaceuticals Inc

Exchange NASDAQ
Headquaters Edison, NJ, United States
IPO Launch date 2014-02-11
Interim CEO, Interim CFO & Chairman of the Board Mr. John Patrick Brancaccio C.P.A.
Sector Healthcare
Industry Biotechnology
Full time employees 22
Full time employees 22

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor is in Phase 2b clinical trial to target multiple pathologic pathways involved in the progression of liver disease and treat non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​